IBD-RESPONSE is a UK-wide multi-centre observational cohort study that will develop a predictive algorithm for response or failure to respond to biologic, janus kinase inhibitor (JAKi) and sphingosine-1-phosphate receptor (S1PR) modulator therapies in Crohn's disease and ulcerative colitis.
Launched in 2022 our precision medicine research will follow 1,325 patients for the first year after commencing one of these therapies.
We will utilise multiple cutting edge technologies to study the gut microbiome, the human genome and immune system integrated with clinical outcome data utilising machine learning techniques.
Click on the image to watch our video and find out more
Meet the team of clinicians and scientists that are working hard to set up IBD-RESPONSE at 40 centres across the UK
IBD-RESPONSE may shape how clinicians and patients tailor individual treatment choices for IBD in the future
Read more about CD-metaRESPONSE and how it differs to and complements IBD-RESPONSE
Find out more information about the study from our Chief Investigator, and how your involvement will make a difference to the future of IBD treatment
If you'd like to get in touch with us to find out more information, please follow the 'contact us' tab in the menu above.
Check below to see a summary of our published work within IBD-RESPONSE
Click on the link below to read the protocol for both IBD-RESPONSE and CD-metaRESPONSE
Protocol paper
Read about our latest letter, published in Gut, which investigates the impact of different storage times and temperatures on the plasma metabolome.
Summary Research letter
